Skill Checkup: A 70-Year-Old Man With Loss of Smell, Dry Cough, and Headache

Enrico Brunetti, MD


November 07, 2022

Because the patient's age and weight, as well as preexisting diabetes and hypertension, put him at high risk for COVID-19 hospitalization, antiviral therapy would be an appropriate treatment option in this case. World Health Organization (WHO) guidelines on COVID-19 strongly recommend that patients at high risk of progressing to severe disease should take up a course of ritonavir-boosted nirmatrelvir (paxlovid). The WHO also offers a weaker recommendation for remdesivir or molnupiravir. While the WHO previously recommended mAbs, sotrovimab, and casirivimab-imdevimab for patients at high risk for COVID-19 progression, these agents are no longer recommended.

Based on these recommendations, the patient begins a 5-day course of ritonavir-boosted nirmatrelvir.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.